Member Info for Wilson63

Hi Kaeren, do we know for certain Gemma Stokes 10 min test has been shelved?, night just be a bit of a holy grail that's difficult to achieve.

Byp anybody losing a job it isn't nice but how could we justify 280+ on the revenues coming in?

What was your take on the presentation CS?

Hi Drb where is that info re no it-is sales in the uk etc and the payment to Gm, I've scrolled up and down and keep missing it.

Johnny I can't answer but I just voted for in person meetings
Agree the questions were a dawdle and they do themselves a dis service which I have told them on feedback

However to me it sounds a lot going on GM done no forward thinking but DA presented much better this time and I actually enjoyed the presentation part.

Tks B2

Page 8 total assets 166 million

Valued at 54 million

#outfrombehindsofa

Oops missed out the important bit, 4 mil is very poor guidance.

Back home I hung my hat on 8.5 mil for h2 as that was the companies guidance backed by there statement that the 8 new Non covid pcr's would be launched in q4, quite obviously(hopefully) they are not included in current guidance, but surely a line(have I missed it) saying, however when 8 non covid pcr's are launched q4 we expect a significant uptick in revenues.

Good news about Clonit spotted through LinkedIn by other posters I believe.

Now the presentation!!!! as a positive shareholder I have set up my settee so I can hide behind it.

Shout out to Exmex and B2

These developments bring together extraction capability, automated sample preparation, and broad menu expansion. We expect this to deliver a competitive market offering for rapid turnaround time, routine testing in our target areas of mid to low volume "spoke" laboratories and non-routine services in "hub" laboratories.

Just a reminder before we get any one day visitors
H1 was 16.5 mil revenues as announced, this has been known about for weeks and weeks

expected 8.5 mil second half(see if we get any forward guidance.

8 pcr tests NON covid to be launched in Q4, this was announced in January.

Driving for a few hours now so good luck to all.

Oh yes big day for Ceo, needs to present well.

On 30 March 2022, Novacyt was granted a key patent in relation to ORF1a/b, which will lead to a corporation tax credit against future profits and is back dated to the original patent submission date in October 2020

Sorry I've missed where he/she/it said the following

"p100 is entitled to his view...personally i don't agree..... and though will probably miss attending due to work will be trying to find a recording later in the day"!!!!!

Here you are CS

I can assure you I won’t be tuning into that absolute garbage.

absolute shizer on a continual basis all egging each other on like bloody gremlins, some of the weirdest investors!!!!! I've came across
Once again you need it explaining(but you know that) constructive is not

"I can assure you I won’t be tuning into that absolute garbage." as said by our esteemed shareholder pl100

Proper way to look after he/she/its investment.

Constructive comments captain swag means exactly that , for your benefit

We are getting bought tomorrow-: not constructive.

This will be 0p tomorrow not constructive

You getting the drift? Mind you even a lol can mean different things to people about here.

I said earlier

I'm willing to wait until H2's results are out early next year although Rns's will give us a general steer.

Should read, to see some progress.

Ok so let's put all the known figures out there for tomorrow so we can constructively look at what is said
H1 revenues 16.5 mil of which 3.5 was non covid this is what the presentation is primarily about.
The company have only predicted 8.5 million revenues mainly focussed in Q4 for H2 reliant on the eight pcr's due to be launched in Q4, they made a statement to this effect in January , they must make some comments with regards to these products at the end/during the presentation
tomorrow.
I'm willing to wait until H2's results are out early next year although Rns's will give us a general steer.
Just my thoughts, just over 24 hours to wait.

As ever constructive comments welcome we knew these figures months ago so no swooned or screamers welcome.

CS I was thinking you thought any info posted on this board had no influence on the sp?

Yes if the traders are so minded to announce their buys and sell perhaps they should do it at the time, would make their fantastic judgment a bit more believable.

Think you'll find the small band of lth's who post on here don't hate GM he had a ltip and got"lucky" if that's an appropriate word for a pandemic done great m and a with it-is and as long as we win the dhsc dispute in my eyes he's perfectly entitled to his money, however he didn't prep us for post covid and that has been left to the current ceo who's having to wait on everything coming through validation before he can launch.

Handy acknowledged I'd done by own before I went down that far on the thread.

Ok Tks to alistair m...... on twitter part translation

Novacyt jumps by more than 25% now to 1.07 euros in a thick volume representing nearly 1% of the capital. In the absence of a tangible element explaining this rally, we can imagine that some daring investors draw a parallel with the Theradiag case (+58.6%), which will be the subject of a takeover bid of its shareholder at 25.07% Biosynex. Biosynex has also been a shareholder of Novacyt since February. The group had notified a 4.49% stake in July.

Biosynex, whose results had soared during the pandemic, has taken various participations. Last week, the group also announced the acquisition of Bigix Pharma in Italy, which distributes different product lines in the medical equipment segment and had achieved a turnover of about 2.9 ME in 2021.

Source

https://www.boursedirect.fr/fr/actualites/categorie/divers/novacyt-flambe-avec-les-speculations-boursier-e25bf8be7c1dc1b7d4fa00216a991777cfcef27e